[
    [
        {
            "time": "",
            "original_text": "医药生物行业6月投资策略：后疫情时代 把握恢复性子行业和医药“新基建”增量赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "后疫情时代",
                    "恢复性子行业",
                    "医药新基建",
                    "增量赛道"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业6月投资策略：后疫情时代 把握恢复性子行业和医药“新基建”增量赛道",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【民生医药|周报】：不确定外部环境下，中国市场红利持续",
            "features": {
                "keywords": [
                    "民生医药",
                    "周报",
                    "不确定外部环境",
                    "中国市场红利"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|周报】：不确定外部环境下，中国市场红利持续",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【民生医药|外包】不确定外部环境下，中国市场红利持续",
            "features": {
                "keywords": [
                    "民生医药",
                    "外包",
                    "不确定外部环境",
                    "中国市场红利"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "外包"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|外包】不确定外部环境下，中国市场红利持续",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]